Rescreening Gets A Boost
As Pap smear technology advances, lines are being drawn in the sand between product companies and their pathologist and physician customers. Neuromedical Systems' aggressive consumer marketing campaign warned women that Pap smears alone aren't enough to accurately diagnose cervical cancer, that the company's new rescreening technology. But physicians are up in arms, concerned that the company is getting them into potential liability troubles if they don't rescreeen.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.